This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...
The global oligonucleotide CDMO market is poised for growth driven by the rising clinical pipeline of RNA-based therapies, increased mRNA therapeutic adoption, and biotech firms outsourcing to reduce ...
ST Pharm has struck a deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for an ...
As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...
Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Market Industry Trends and Global Forecasts to 2035: By Application Area, Type of Product Synthesized, Type of Oligonucleotide ...
The use of oligonucleotides as therapeutic agents is of great interest, particularly when it comes to siRNA and antisense oligonucleotides. However, the difficulty of targeting the right organ and ...
RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively ...
In this Teach Me in 10, Dr. Amanda Lee, Product Marketing Manager at Thermo Fisher Scientific, explains how optimizing mass ...
When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...
STA Pharmaceutical, the active pharmaceutical ingredient (API) manufacturing arm of WuXi AppTec, has opened a large-scale oligonucleotide API plant in Changzhou, China. The 2,800 m 2 facility is ...
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis Market: Forecast by Oligo Length, Application, Category, Type, Product, and Region, with Executive and Consultant Guides" report has been added ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results